Frequently Asked Questions
The market is segmented based on Global Angiotensin Converting Enzyme (ACE) Inhibitors Market , By Product Type (Dicarboxylate-Containing Agents, Phosphonate-Containing Agents, Sulfhydryl-Containing Agents), Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), Dosage Form (Oral Tablets, Oral Solution), Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce Websites, Online Drug Stores) – Industry Trends and Forecast to 2030.
.
The Global Angiotensin Converting Enzyme Ace Inhibitors Market size was valued at USD 3456.27 USD Million in 2022.
The Global Angiotensin Converting Enzyme Ace Inhibitors Market is projected to grow at a CAGR of 4.9% during the forecast period of 2023 to 2030.
The major players operating in the market include Novartis, Pfizer, Merck, AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Teva Pharmaceutical Industries, Lupin, Cipla, Torrent Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cadila Healthcare, Macleods Pharmaceuticals, Zydus Cadila, Mylan, Sandoz, Accord Healthcare, Apotex.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
